sur Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Restructures Management for Growth
Viromed Medical AG, a leader in cold plasma technology, announces a significant restructuring of its Management Board. Founder Uwe Perbandt will resign by the end of December 2026. Christian Strauch will join the board on November 16, 2026, for a nearly three-year term. Strauch is expected to guide Viromed through its next growth phase with his substantial sales expertise.
The Supervisory Board, led by Dr. Thomas Gutschlag, is committed to this strategic transition. Strauch's extensive experience in scaling healthcare companies, including his roles with pharmedix GmbH and other pharmaceutical ventures, positions him as a valuable asset for Viromed's future.
Perbandt expressed pride in Viromed's achievements and confidence in Strauch as his successor. With a solid foundation in place, the company is poised to expand the application of its technology and capitalize on emerging market opportunities.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Viromed Medical AG